News for AstraZeneca PLC (AZN)

MSFT, AZN, and BLK earn praise in fresh Zacks reports, with AI, pharma pipelines, and AUM growth fueling long-term outlooks.

Market Analysis by covering: Microsoft Corporation, Apple Inc, Amazon.com Inc, NVIDIA Corporation. Read 's Market Analysis on Investing.com

Jefferies has started coverage on Mineralys Therapeutics (MLYS) with a Hold rating, setting a price target of $15. Mineralys is developing an innovative blood p

AstraZeneca (AZN) is poised to be affected by a significant restructuring of the U.S. vaccine advisory process. Recent announcements indicate a complete reconst

Market Analysis by covering: Euro US Dollar, British Pound US Dollar, US Dollar Japanese Yen, FTSE 100. Read 's Market Analysis on Investing.com

Amidst various pharmaceutical and vaccine companies, AstraZeneca (AZN) stands as a significant player. This company, alongside others in the industry, drives in

The issue of vaccine trust is becoming increasingly contentious in the U.S., and AstraZeneca (AZN) finds itself at the center of the discussion. Public confiden

AstraZeneca (AZN) has commenced the DESTINY-Endometrial01 phase 3 clinical trial, marking the first administration of the study's treatment. This trial is desig

IonQ Inc. (IONQ) shares rose over 11% to $43.41 in premarket trading after announcing a $1.075 billion acquisition of Oxford Ionics, including $1.065 billion in stock and $10 million in cash, to advance trapped-ion quantum computing and support US-UK technological collaboration. The acquisition accelerates IonQ’s goal to develop fault-tolerant quantum…

IonQ (IONQ) announced results of a research program between the company, AstraZeneca (AZN), Amazon Web Services (AMZN) and Nvidia (NVDA).

PR NewswireNEW YORK, June 7, 2025 NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc. ("

An observational study has highlighted a potential eye health risk for diabetes patients using GLP-1 medications, including those produced by AstraZeneca (AZN).

The European Union has granted approval to AstraZeneca's (AZN) Calquence, in combination with venetoclax, with or without obinutuzumab, for treating adults with

Perrigo has announced that Matt Winterman will become the company's new Executive Vice President, Product Supply, Operations Strategy and Transformation Officer

Market Analysis by covering: Euro Stoxx 50, Novartis AG ADR, Sanofi ADR, GSK plc DRC. Read 's Market Analysis on Investing.com

Key Highlights: AstraZeneca's (AZN) phase 3 trial reveals significant advancements in HER2-positive metastatic breast cancer treatment. Enhertu and Perje

Truist analyst Asthika Goonewardene has highlighted recent developments in the pharmaceutical sector, following Bristol Myers Squibb's collaboration with BioNTe

AstraZeneca (AZN) and Daiichi Sankyo have announced promising outcomes from the DESTINY-Breast09 Phase III trial. Their drug combination, ENHERTU plus pertuzuma

AstraZeneca (AZN) has announced promising outcomes from the Phase III SERENA-6 trial, which assessed the effectiveness of its drug camizestrant in treating adva